FIELD: medicine.
SUBSTANCE: invention refers to medicine and concerns an isolated polypeptide containing a cleavable moiety (CM) containing an amino acid sequence selected from a group consisting of SEQ ID NO: 459–469 and 31, where the cleaved fragment is a substrate for a matrix metalloprotease.
EFFECT: invention provides cleavage of the recovered polypeptide by matrix metalloprotease.
15 cl, 7 dwg, 10 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-CD71 CONJUGATES ACTIVATED ANTIBODY-DRUG AND THEIR APPLICATION METHODS | 2018 |
|
RU2771292C2 |
| ACTIVATED ANTIBODIES WHICH BIND TO EPIDERMAL GROWTH FACTOR RECEPTOR, AND METHODS FOR USE THEREOF | 2013 |
|
RU2713121C2 |
| MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATED ANTIBODIES AND METHODS OF USE THEREOF | 2014 |
|
RU2815683C2 |
| MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATED ANTIBODIES AND METHODS OF THEIR APPLICATION | 2014 |
|
RU2727836C2 |
| POLYSPECIFIC POLYPEPTIDE CONSTRUCTS WITH LIMITED BINDING TO CD3 AND METHODS OF THEIR APPLICATION | 2018 |
|
RU2813816C2 |
| COMPOSITIONS OF MODIFIED ANTIBODIES, METHODS FOR THEIR PRODUCTION AND USE | 2010 |
|
RU2799787C2 |
| MODIFIED ANTIBODIES COMPOSITION, METHODS OF PRODUCTION AND APPLICATION | 2010 |
|
RU2636046C2 |
| BINDING MOLECULES SPECIFIC FOR ASCT2, AND THEIR USE | 2016 |
|
RU2710194C2 |
| HUMANIZED ANTIBODIES AGAINST CD269 (BCMA) | 2015 |
|
RU2749041C2 |
| "ANTIBODY-DRUG" CONJUGATES | 2012 |
|
RU2624141C2 |
